Compare Charter Communications Inc (CHTR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs Novo Nordisk A/S — how do they compare? Charter Communications Inc trades at $130.95 (market cap $15.73B), while Novo Nordisk A/S trades at $50.5 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 13.7× Charter Communications Inc's market cap, and Novo Nordisk A/S pays a 3.67% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| CHTR | NVO | |
|---|---|---|
Market Cap | $15.73B | $214.94B |
Sector | Media | Health |
52-Week High | $398.11 | $71.70 |
52-Week Low | $125.54 | $35.29 |
Enterprise Value | $112.04B | $233.91B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charter Communications (CHTR) trades at $131.37, up 0.49% today, amid mixed technical signals with a bearish moving average trend but bullish oscillators. The stock appears deeply undervalued with a P/E of 3.55 and EV/EBITDA of 5.3, supported by a 9.03% net income margin and strong cash flow. Recent news highlights potential strategic partnerships with SpaceX and acquisition interest from Comcast, driving investor optimism despite recent earnings misses.
The outlook for CHTR is cautiously optimistic, with significant upside potential based on analyst consensus targets near $196.20. Key opportunities include valuation discount, cash flow inflection, and strategic moves, while risks involve high debt levels, competitive pressures, and execution on subscriber growth. The stock's current level near support at $130 suggests a critical juncture for near-term direction.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
